David Gandara, Co-Director of the Center for Experimental Therapeutics at the UC Davis Comprehensive Cancer Center, shared Samuel Hume’s, Fellow at The Foulkes Foundation and pursuing PhD in the University of Oxford’s Department of Oncology, post on X, adding:
“Re- fast FDA approval for daraxonrasib in pancreas cancer, while we are all cheering this fantastic advance, the sobering news is the all time high oral drug price, set at $480,000/year, $663/pill.
NY Times says this is the ‘New Normal’. I hope not!”
Quoting Samuel Hume’s post:
“At 135 days between data and approval, daraxonrasib for pancreas cancer becomes the fastest FDA-approval of the year – by far.”
You can also read: FDA Approves Daraxonrasib: First-in-Class RAS Inhibitor for Metastatic Pancreatic Cancer
